Loading...
Loading...
MYOV| Name | Value |
|---|---|
| Revenues | 100.2M |
| Cost of Revenue | 34.2M |
| Gross Profit | 66.0M |
| Operating Expense | 117.9M |
| Operating I/L | -51.9M |
| Other Income/Expense | -4.5M |
| Interest Income | 1.6M |
| Pretax | -56.4M |
| Income Tax Expense | 1.2M |
| Net Income/Loss | -57.6M |
Myovant Sciences Ltd. is a biopharmaceutical company focused on developing innovative treatments for women's and men's health. The company's lead product, relugolix, is an oral, once-daily, small molecule used to treat heavy menstrual bleeding related to uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. Additionally, Myovant Sciences is developing MVT-602, a kisspeptin agonist, for the treatment of female infertility in assisted reproduction. The company has a collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health, driving its revenue through product development and commercialization.
